Key facts
- This page summarizes Christopher Martell's Form 4 filing for Candel Therapeutics, Inc. (CADL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Jun 2025, 08:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025.
Footnote F2
Shares held by Spouse.
Footnote F3
Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
Footnote F4
Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.